scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001077473 |
P356 | DOI | 10.1186/1742-4690-5-78 |
P932 | PMC publication ID | 2563025 |
P698 | PubMed publication ID | 18778482 |
P5875 | ResearchGate publication ID | 23244328 |
P50 | author | Nuno Taveira | Q42305919 |
Francisco Antunes | Q43153431 | ||
Perpétua Gomes | Q54603815 | ||
Helena Barroso | Q55302937 | ||
Pedro Borrego | Q56854274 | ||
Cheila Rocha | Q56854288 | ||
José Maria Marcelino | Q56975479 | ||
Carlos Novo | Q57447046 | ||
P2093 | author name string | Fernando Maltez | |
Manuela Doroana | |||
P2860 | cites work | The causes and consequences of HIV evolution | Q22251040 |
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools | Q24248165 | ||
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection | Q24538985 | ||
Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant | Q24815687 | ||
Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort | Q24815853 | ||
Confidence Limits on Phylogenies: an Approach using the Bootstrap | Q26778379 | ||
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0 | Q26778434 | ||
MODELTEST: testing the model of DNA substitution | Q26778437 | ||
Evolutionary trees from DNA sequences: A maximum likelihood approach | Q27860898 | ||
Human immunodeficiency virus type 2 | Q28218992 | ||
Reduced rate of disease development after HIV-2 infection as compared to HIV-1 | Q28237927 | ||
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin | Q28264707 | ||
HyPhy: hypothesis testing using phylogenies | Q29013475 | ||
Antibody neutralization and escape by HIV-1 | Q29547345 | ||
Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
Unifying the epidemiological and evolutionary dynamics of pathogens | Q29619092 | ||
Slower heterosexual spread of HIV-2 than HIV-1. | Q30419674 | ||
Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope | Q33269794 | ||
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics | Q33274194 | ||
Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission | Q33783504 | ||
Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes | Q33803939 | ||
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection | Q33825654 | ||
HIV evolutionary dynamics within and among hosts | Q34000621 | ||
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins | Q34430673 | ||
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals | Q34437201 | ||
Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity | Q35101464 | ||
Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection | Q35185919 | ||
Identifying epitopes of HIV-1 that induce protective antibodies | Q35708836 | ||
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies | Q35784605 | ||
Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections | Q35857480 | ||
Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection | Q35857567 | ||
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120 | Q35870879 | ||
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS | Q35895520 | ||
Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts | Q35994354 | ||
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection | Q36483346 | ||
Improving on nature: focusing the immune response on the V3 loop. | Q36487155 | ||
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline | Q36526893 | ||
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing | Q36540055 | ||
Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences | Q36637273 | ||
Exploiting the defensive sugars of HIV-1 for drug and vaccine design | Q36802333 | ||
Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies | Q36884458 | ||
Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes | Q36960293 | ||
Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers | Q38906206 | ||
Genetic variability of human immunodeficiency virus type 2 C2V3 region within and between individuals from Bissau, Guinea-Bissau, West Africa | Q39340240 | ||
The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization | Q39362853 | ||
Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay | Q39446427 | ||
Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. | Q39685744 | ||
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution | Q40060900 | ||
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation | Q40349284 | ||
Humoral immunity and the evolution of HIV-2. | Q43218253 | ||
HIV-2-infected patients survive longer than HIV-1-infected patients. | Q43712041 | ||
CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site | Q45419807 | ||
Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. | Q45420512 | ||
Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood | Q45524572 | ||
A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients | Q45557943 | ||
Widespread adaptive evolution in the human immunodeficiency virus type 1 genome | Q45710774 | ||
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection | Q45724156 | ||
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection | Q45739618 | ||
Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load | Q45743456 | ||
Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. | Q45746519 | ||
Intrapatient Variability of the Human Immunodeficiency Virus Type 2 Envelope V3 Loop | Q45788570 | ||
Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection | Q46908458 | ||
Long-term intrapatient viral evolution during HIV-2 infection | Q46977891 | ||
Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression | Q47872743 | ||
Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions | Q48078795 | ||
Evidence for negative selective pressure in HIV-2 evolution in vivo | Q48148785 | ||
The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. | Q52312661 | ||
In vitro replication capacity of HIV-2 variants from long-term aviremic individuals | Q56880140 | ||
N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization | Q56935643 | ||
Plasma Viral Load Threshold for Sustaining Intrahost HIV Type 1 Evolution | Q58415389 | ||
N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes | Q67701330 | ||
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection | Q70573580 | ||
Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection | Q77296161 | ||
Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infection | Q81270975 | ||
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 78 | |
P577 | publication date | 2008-09-08 | |
P1433 | published in | Retrovirology | Q15793508 |
P1476 | title | The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients | |
P478 | volume | 5 |
Q34062608 | A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1. |
Q37517645 | A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support |
Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
Q33591409 | Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response |
Q33809419 | Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection |
Q36651031 | HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development |
Q33966596 | HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients |
Q37001043 | Isolation of a new HIV-2 group in the US. |
Q58546281 | LOW-BIAS RNA SEQUENCING OF THE HIV-2 GENOME FROM BLOOD PLASMA |
Q60917430 | Low Postseroconversion CD4 T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection |
Q34039423 | Origin and epidemiological history of HIV-1 CRF14_BG. |
Q34290973 | Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy |
Q35115656 | Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes. |
Q92547213 | Variation in Intra-individual Lentiviral Evolution Rates: a Systematic Review of Human, Nonhuman Primate, and Felid Species |
Search more.